Abstract
Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will present with locally advanced disease, requiring multimodality therapy. While this approach has a curative intent, a significant subset of these patients will develop locoregional failure and/or distant metastases. The prognosis of these patients is poor, and therapeutic options other than palliative chemotherapy are urgently needed. Epidermal growth factor receptor (EGFR) overexpression is an important factor in the pathogenesis of HNSCC, and a decade ago, the EGFR targeting monoclonal antibody cetuximab was approved for the treatment of late-stage HNSCC in different settings. In 2016, the anti-programmed death-1 (PD-1) immune checkpoint inhibitors nivolumab and pembrolizumab were both approved for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy, and in 2019, pembrolizumab was approved for first-line treatment (either as monotherapy in PD-L1 expressing tumors, or in combination with chemotherapy). Currently, trials are ongoing to include immune checkpoint inhibition in the (neo)adjuvant treatment of HNSCC as well as in novel combinations with other drugs in the recurrent/metastatic setting to improve response rates and survival and help overcome resistance mechanisms to immune checkpoint blockade. This article provides a comprehensive review of the management of head and neck cancers in the current era of immunotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Global Cancer Observatory. International Agency for Research on Cancer. World Health Organization. https://gco.iarc.fr
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
Gupta B, Bray F, Kumar N, Johnson NW. Associations between oral hygiene habits, diet, tobacco and alcohol and risk of oral cancer: a case-control study from India. Cancer Epidemiol. 2017;51:7–14.
Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80.
Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294–301.
Garnaes E, Kiss K, Andersen L, Therkildsen MH, Franzmann MB, Filtenborg-Barnkob B, et al. A high and increasing HPV prevalence in tonsillar cancers in Eastern Denmark, 2000–2010: the largest registry-based study to date. Int J Cancer. 2015;136(9):2196–203.
Hannisdal K, Schjolberg A, De Angelis PM, Boysen M, Clausen OP. Human papillomavirus (HPV)-positive tonsillar carcinomas are frequent and have a favourable prognosis in males in Norway. Acta Otolaryngol. 2010;130(2):293–9.
Nasman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer. 2009;125(2):362–6.
Rietbergen MM, Leemans CR, Bloemena E, Heideman DA, Braakhuis BJ, Hesselink AT, et al. Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. Int J Cancer. 2013;132(7):1565–71.
de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70.
O’Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17(4):440–51.
Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33(29):3235–42.
Taberna M, Mena M, Pavon MA, Alemany L, Gillison ML, Mesia R. Human papillomavirus-related oropharyngeal cancer. Ann Oncol. 2017;28(10):2386–98.
Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, et al. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA. 2012;307(7):693–703.
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.
Agalliu I, Gapstur S, Chen Z, Wang T, Anderson RL, Teras L, et al. Associations of Oral alpha-, beta-, and gamma-Human Papillomavirus Types With Risk of Incident Head and Neck Cancer. JAMA Oncol. 2016;2(5):599–606.
D’Souza G, Gross ND, Pai SI, Haddad R, Anderson KS, Rajan S, et al. Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. J Clin Oncol. 2014;32(23):2408–15.
Nielsen KJ, Jakobsen KK, Jensen JS, Gronhoj C, Von Buchwald C. The effect of prophylactic HPV vaccines on oral and oropharyngeal HPV infection—a systematic review. Viruses. 2021;13(7).
Snijders PJ, Cromme FV, van den Brule AJ, Schrijnemakers HF, Snow GB, Meijer CJ, et al. Prevalence and expression of human papillomavirus in tonsillar carcinomas, indicating a possible viral etiology. Int J Cancer. 1992;51(6):845–50.
de Villiers EM, Weidauer H, Otto H, zur Hausen HH. Papillomavirus DNA in human tongue carcinomas. Int J Cancer. 1985;36(5):575–8.
Hausen zur H. Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol. 1977;78:1–30.
Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92(9):709–20.
Slebos RJ, Yi Y, Ely K, Carter J, Evjen A, Zhang X, et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res. 2006;12(3 Pt 1):701–9.
Smeets SJ, Braakhuis BJ, Abbas S, Snijders PJ, Ylstra B, van de Wiel MA, et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene. 2006;25(17):2558–64.
Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27.
Hudelist G, Manavi M, Pischinger KI, Watkins-Riedel T, Singer CF, Kubista E, et al. Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol. 2004;92(3):873–80.
Yu T, Ferber MJ, Cheung TH, Chung TK, Wong YF, Smith DI. The role of viral integration in the development of cervical cancer. Cancer Genet Cytogenet. 2005;158(1):27–34.
Palefsky JM, Holly EA. Molecular virology and epidemiology of human papillomavirus and cervical cancer. Cancer Epidemiol Biomark Prev. 1995;4(4):415–28.
Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol. 1989;63(10):4417–21.
Dupuy C, Buzoni-Gatel D, Touze A, Le Cann P, Bout D, Coursaget P. Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles. Microb Pathog. 1997;22(4):219–25.
Hinds P, Finlay C, Levine AJ. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol. 1989;63(2):739–46.
Masuda H, Miller C, Koeffler HP, Battifora H, Cline MJ. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA. 1987;84(21):7716–9.
Havre PA, Yuan J, Hedrick L, Cho KR, Glazer PM. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res. 1995;55(19):4420–4.
Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993;75(3):495–505.
Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990;248(4951):76–9.
Pagano M, Durst M, Joswig S, Draetta G, Jansen-Durr P. Binding of the human E2F transcription factor to the retinoblastoma protein but not to cyclin A is abolished in HPV-16-immortalized cells. Oncogene. 1992;7(9):1681–6.
Demers GW, Foster SA, Halbert CL, Galloway DA. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc Natl Acad Sci USA. 1994;91(10):4382–6.
Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 1985;314(6006):111–4.
Tommasino M, Adamczewski JP, Carlotti F, Barth CF, Manetti R, Contorni M, et al. HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene. 1993;8(1):195–202.
Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015 Jan 29;517(7536):576-82.
Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, et al. Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A. 2014;111(43):15544–9.
Hajek M, Sewell A, Kaech S, Burtness B, Yarbrough WG, Issaeva N. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma. Cancer. 2017;123(10):1778–90.
Zhang JHC, Yang X, Guven E, Nussinov R, Chen Z, VanWaes C. Defective TRAF3 modulates alternative NF-kB signaling and cytokine expression to promote cancer cell survival in HPV positive head and neck cancer (TUM10P1049). J Immunol. 2015;194(211):30.
Banoczy J, Csiba A. Comparative study of the clinical picture and histopathologic structure of oral leukoplakia. Cancer. 1972;29(5):1230–4.
Gupta PC, Mehta FS, Daftary DK, Pindborg JJ, Bhonsle RB, Jalnawalla PN, et al. Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. Community Dent Oral Epidemiol. 1980;8(6):283–333.
Kramer IR, Lucas RB, Pindborg JJ, Sobin LH. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol. 1978;46(4):518–39.
Li S, Lee YC, Li Q, Chen CJ, Hsu WL, Lou PJ, et al. Oral lesions, chronic diseases and the risk of head and neck cancer. Oral Oncol. 2015;51(12):1082–7.
Loftus ER, Baric JM, Kapur KK, Chauncey HH. Cigarette smoking and oral leukoplakia in healthy males. Spec Care Dentist. 1981;1(5):206–10.
Shibuya H, Amagasa T, Seto K, Ishibashi K, Horiuchi J, Suzuki S. Leukoplakia-associated multiple carcinomas in patients with tongue carcinoma. Cancer. 1986;57(4):843–6.
Silverman S Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation A follow-up study of 257 patients. Cancer. 1984;53(3):563–8.
Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med. 2008;37(1):1–10.
Shubhasini AR, Praveen BN, Hegde U, Uma K, Shubha G, Keerthi G, et al. Inter- and intra-observer variability in diagnosis of oral dysplasia. Asian Pac J Cancer Prev. 2017;18(12):3251–4.
van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol. 2009;45(4–5):317–23.
Partridge M, Pateromichelakis S, Phillips E, Emilion GG, A’Hern RP, Langdon JD. A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res. 2000;60(14):3893–8.
Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6(5):963–8.
Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 1996;56(11):2488–92.
Tabor MP, Brakenhoff RH, van Houten VM, Kummer JA, Snel MH, Snijders PJ, et al. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res. 2001;7(6):1523–32.
Roesch-Ely M, Nees M, Karsai S, Ruess A, Bogumil R, Warnken U, et al. Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer. Oncogene. 2007;26(1):54–64.
Schaaij-Visser TB, Graveland AP, Gauci S, Braakhuis BJ, Buijze M, Heck AJ, et al. Differential proteomics identifies protein biomarkers that predict local relapse of head and neck squamous cell carcinomas. Clin Cancer Res. 2009;15(24):7666–75.
Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Kummer JA, Leemans CR, Braakhuis BJ. Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin Cancer Res. 2004;10(11):3607–13.
Bhatia A, Burtness B. Novel molecular targets for chemoprevention in malignancies of the head and neck. Cancers (Basel). 2017;9(9).
Benner SE, Pajak TF, Lippman SM, Earley C, Hong WK. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst. 1994;86(2):140–1.
Bhatia AK, Lee JW, Pinto HA, Jacobs CD, Limburg PJ, Rubin P, et al. Double-blind, randomized Phase III trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer. 2017;123(23):4653–62.
Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986;315(24):1501–5.
Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990;323(12):795–801.
Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006;98(7):441–50.
Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, Rudy S, et al. Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res. 2004;10(5):1565–73.
Papadimitrakopoulou VA, William WN Jr, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res. 2008;14(7):2095–101.
William WN Jr, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, et al. Erlotinib and the risk of oral cancer: the Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol. 2016;2(2):209–16.
Agarwal R, Mukhtar H. Cancer chemoprevention by polyphenols in green tea and artichoke. Adv Exp Med Biol. 1996;401:35–50.
Kim JW, Amin AR, Shin DM. Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prev Res (Phila). 2010;3(8):900–9.
Knobloch TJ, Uhrig LK, Pearl DK, Casto BC, Warner BM, Clinton SK, et al. Suppression of proinflammatory and prosurvival biomarkers in oral cancer patients consuming a black raspberry phytochemical-rich troche. Cancer Prev Res (Phila). 2016;9(2):159–71.
Negri E, Franceschi S, Bosetti C, Levi F, Conti E, Parpinel M, et al. Selected micronutrients and oral and pharyngeal cancer. Int J Cancer. 2000;86(1):122–7.
Schwartz JL, Baker V, Larios E, Chung FL. Molecular and cellular effects of green tea on oral cells of smokers: a pilot study. Mol Nutr Food Res. 2005;49(1):43–51.
Seeram NP, Adams LS, Henning SM, Niu Y, Zhang Y, Nair MG, et al. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem. 2005;16(6):360–7.
Warner BM, Casto BC, Knobloch TJ, Accurso BT, Weghorst CM. Chemoprevention of oral cancer by topical application of black raspberries on high at-risk mucosa. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;118(6):674–83.
Yang CS, Wang ZY. Tea and cancer. J Natl Cancer Inst. 1993;85(13):1038–49.
Hanna GJ VA, Shi R, O’Neill A, Liu M, Quinn CT, Curtin RK, Flynn M, Treister NS, Sroussi HY, Vacharotayangul P, Goguen LA, Annino DJ, Rettig EM, Jo VY, Wong K, Uppaluri R, Haddad R, Woo SB. A phase II study of nivolumab for high-risk oral leukoplakia. In: AoOsS-S, editor. ESMO 2022; Paris; 2022. https://doi.org/10.1016/annonc/annonc1056 .
Tandon S, Shahab R, Benton JI, Ghosh SK, Sheard J, Jones TM. Fine-needle aspiration cytology in a regional head and neck cancer center: comparison with a systematic review and meta-analysis. Head Neck. 2008;30(9):1246–52.
Adoga AA, Silas OA, Nimkur TL. Open cervical lymph node biopsy for head and neck cancers: any benefit? Head Neck Oncol. 2009;29(1):9.
Huang SH, O’Sullivan B. Overview of the 8th edition TNM Classification for Head and Neck Cancer. Curr Treat Options Oncol. 2017;18(7):40.
Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol. 2014;32(34):3858–66.
Lydiatt WM, Patel SG, O’Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):122–37.
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.
Husain ZA, Chen T, Corso CD, Wang Z, Park H, Judson B, et al. A Comparison of prognostic ability of staging systems for human papillomavirus-related oropharyngeal squamous cell carcinoma. JAMA Oncol. 2017;3(3):358–65.
Tang LL, Chen YP, Mao YP, Wang ZX, Guo R, Chen L, et al. Validation of the 8th edition of the UICC/AJCC Staging System for nasopharyngeal carcinoma from endemic areas in the intensity-modulated radiotherapy era. J Natl Compr Canc Netw. 2017;15(7):913–9.
Tang LQ, Li CF, Li J, Chen WH, Chen QY, Yuan LX, et al. Establishment and validation of prognostic nomograms for endemic nasopharyngeal carcinoma. J Natl Cancer Inst. 2016;108(1).
Lee VH, Kwong DL, Leung TW, Choi CW, O’Sullivan B, Lam KO, et al. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. Int J Cancer. 2019;144(7):1713–22.
Xu C, Chen YP, Liu X, Li WF, Chen L, Mao YP, et al. Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy. Oral Oncol. 2017;69:99–107.
Chan ATC, Hui EP, Ngan RKC, Tung SY, Cheng ACK, Ng WT, Lee VHF, Ma BBY, Cheng HC, Wong FCS, Loong HHF, Tong M, Poon DMC, Ahuja AT, King AD, Wang K, Mo F, Zee BCY, Chan KCA, Lo YMD. Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. J Clin Oncol. 2018 Jul 10:JCO2018777847. https://doi.org/10.1200/JCO.2018.77.7847. Epub ahead of print. PMID: 29989858.
Guo R, Tang LL, Mao YP, Du XJ, Chen L, Zhang ZC, et al. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma. Cancer. 2019;125(1):79–89.
Leung SF, Chan KC, Ma BB, Hui EP, Mo F, Chow KC, et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol. 2014;25(6):1204–8.
Liu LT, Tang LQ, Chen QY, Zhang L, Guo SS, Guo L, et al. The prognostic value of plasma Epstein-Barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2015;93(4):862–9.
Wheless SA, McKinney KA, Zanation AM. A prospective study of the clinical impact of a multidisciplinary head and neck tumor board. Otolaryngol Head Neck Surg. 2010;143(5):650–4.
Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A, et al. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol. 2015;33(2):156–64.
Lee NCJ, Kelly JR, An Y, Park HS, Judson BL, Burtness BA, et al. Radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma. Cancer. 2019;125(12):2018–26.
Caudell JJ, Gillison ML, Maghami E, Spencer S, Pfister DG, Adkins D, Birkeland AC, Brizel DM, Busse PM, Cmelak AJ, Colevas AD, Eisele DW, Galloway T, Geiger JL, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Mell LK, Mittal BB, Pinto HA, Rocco JW, Rodriguez CP, Savvides PS, Schwartz D, Shah JP, Sher D, St John M, Weber RS, Weinstein G, Worden F, Yang Bruce J, Yom SS, Zhen W, Burns JL, Darlow SD. NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022. J Natl Compr Canc Netw. 2022 Mar;20(3):224–234. https://doi.org/10.6004/jnccn.2022.0016. PMID: 35276673.
Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. Head and neck cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(7):873–98.
Ellis MA, Graboyes EM, Wahlquist AE, Neskey DM, Kaczmar JM, Schopper HK, et al. Primary surgery vs radiotherapy for early stage oral cavity cancer. Otolaryngol Head Neck Surg. 2018;158(4):649–59.
Luryi AL, Chen MM, Mehra S, Roman SA, Sosa JA, Judson BL. Treatment factors associated with survival in early-stage oral cavity cancer: analysis of 6830 cases from the National Cancer Data Base. JAMA Otolaryngol Head Neck Surg. 2015;141(7):593–8.
Mitchell DA, Kanatas A, Murphy C, Chengot P, Smith AB, Ong TK. Margins and survival in oral cancer. Br J Oral Maxillofac Surg. 2018;56(9):820–9.
Sopka DM, Li T, Lango MN, Mehra R, Liu JC, Burtness B, et al. Dysplasia at the margin? Investigating the case for subsequent therapy in “low-risk” squamous cell carcinoma of the oral tongue. Oral Oncol. 2013;49(11):1083–7.
Genden EM, Kotz T, Tong CC, Smith C, Sikora AG, Teng MS, et al. Transoral robotic resection and reconstruction for head and neck cancer. Laryngoscope. 2011;121(8):1668–74.
Moore EJ, Olsen SM, Laborde RR, Garcia JJ, Walsh FJ, Price DL, et al. Long-term functional and oncologic results of transoral robotic surgery for oropharyngeal squamous cell carcinoma. Mayo Clin Proc. 2012;87(3):219–25.
Smith RV, Schiff BA, Garg M, Haigentz M. The impact of transoral robotic surgery on the overall treatment of oropharyngeal cancer patients. Laryngoscope. 2015;125(Suppl 10):S1–15.
Yeh DH, Tam S, Fung K, MacNeil SD, Yoo J, Winquist E, et al. Transoral robotic surgery vs. radiotherapy for management of oropharyngeal squamous cell carcinoma—a systematic review of the literature. Eur J Surg Oncol. 2015;41(12):1603–14.
Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol. 2019;20(10):1349–59.
Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR Trial. J Clin Oncol. 2022;40(8):866–75.
Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, et al. Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN Cancer Research Group Trial (E3311). J Clin Oncol. 2022;40(2):138–49.
Pfister DG, Laurie SA, Weinstein GS, Mendenhall WM, Adelstein DJ, American Society of Clinical O, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006;24(22):3693–704.
Ogol'tsova ES, Paches AI, Matiakin EG, Dvoirin VV, Fedotenko SP, Alferov VS, et al. [Comparative evaluation of the effectiveness of radiotherapy, surgery and combined treatment of stage I-II laryngeal cancer (T1-2NoMo) based on the data of a cooperative randomized study]. Vestn Otorinolaringol. 1990; p. 3–7.
Aaltonen LM, Rautiainen N, Sellman J, Saarilahti K, Makitie A, Rihkanen H, et al. Voice quality after treatment of early vocal cord cancer: a randomized trial comparing laser surgery with radiation therapy. Int J Radiat Oncol Biol Phys. 2014;90(2):255–60.
Mo HL, Li J, Yang X, Zhang F, Xiong JW, Yang ZL, et al. Transoral laser microsurgery versus radiotherapy for T1 glottic carcinoma: a systematic review and meta-analysis. Lasers Med Sci. 2017;32(2):461–7.
Yoo J, Lacchetti C, Hammond JA, Gilbert RW, Neck Cancer Disease Site G. Role of endolaryngeal surgery (with or without laser) versus radiotherapy in the management of early (T1) glottic cancer: a systematic review. Head Neck. 2014;36(12):1807–19.
Guimaraes AV, Dedivitis RA, Matos LL, Aires FT, Cernea CR. Comparison between transoral laser surgery and radiotherapy in the treatment of early glottic cancer: a systematic review and meta-analysis. Sci Rep. 2018;8(1):11900.
Arshad H, Jayaprakash V, Gupta V, Cohan DM, Ambujakshan D, Rigual NR, et al. Survival differences between organ preservation surgery and definitive radiotherapy in early supraglottic squamous cell carcinoma. Otolaryngol Head Neck Surg. 2014;150(2):237–44.
Dahm JD, Sessions DG, Paniello RC, Harvey J. Primary subglottic cancer. Laryngoscope. 1998;108(5):741–6.
Coskun H, Mendenhall WM, Rinaldo A, Rodrigo JP, Suarez C, Strojan P, et al. Prognosis of subglottic carcinoma: Is it really worse? Head Neck. 2019;41(2):511–21.
MacNeil SD, Patel K, Liu K, Shariff S, Yoo J, Nichols A, et al. Survival of patients with subglottic squamous cell carcinoma. Curr Oncol. 2018;25(6):e569–75.
Marchiano E, Patel DM, Patel TD, Patel AA, Xue YE, Eloy JA, et al. Subglottic squamous cell carcinoma: a population-based study of 889 cases. Otolaryngol Head Neck Surg. 2016;154(2):315–21.
Paisley S, Warde PR, O’Sullivan B, Waldron J, Gullane PJ, Payne D, et al. Results of radiotherapy for primary subglottic squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2002;52(5):1245–50.
De Virgilio A, Iocca O, Malvezzi L, Di Maio P, Pellini R, Ferreli F, et al. The emerging role of robotic surgery among minimally invasive surgical approaches in the treatment of hypopharyngeal carcinoma: systematic review and meta-analysis. J Clin Med. 2019;8(2).
Karatzanis AD, Psychogios G, Waldfahrer F, Zenk J, Hornung J, Velegrakis GA, et al. T1 and T2 hypopharyngeal cancer treatment with laser microsurgery. J Surg Oncol. 2010;102(1):27–33.
Martin A, Jackel MC, Christiansen H, Mahmoodzada M, Kron M, Steiner W. Organ preserving transoral laser microsurgery for cancer of the hypopharynx. Laryngoscope. 2008;118(3):398–402.
Park YM, Kim WS, De Virgilio A, Lee SY, Seol JH, Kim SH. Transoral robotic surgery for hypopharyngeal squamous cell carcinoma: 3-year oncologic and functional analysis. Oral Oncol. 2012;48(6):560–6.
Steiner W, Ambrosch P, Hess CF, Kron M. Organ preservation by transoral laser microsurgery in piriform sinus carcinoma. Otolaryngol Head Neck Surg. 2001;124(1):58–67.
Wang CC, Liu SA, Wu SH, Wang CP, Liang KL, Jiang RS, et al. Transoral robotic surgery for early T classification hypopharyngeal cancer. Head Neck. 2016;38(6):857–62.
Hall SF, Groome PA, Irish J, O’Sullivan B. Radiotherapy or surgery for head and neck squamous cell cancer: establishing the baseline for hypopharyngeal carcinoma? Cancer. 2009;115(24):5711–22.
Hall SF, Groome PA, Irish J, O’Sullivan B. The natural history of patients with squamous cell carcinoma of the hypopharynx. Laryngoscope. 2008;118(8):1362–71.
Garden AS, Morrison WH, Clayman GL, Ang KK, Peters LJ. Early squamous cell carcinoma of the hypopharynx: outcomes of treatment with radiation alone to the primary disease. Head Neck. 1996;18(4):317–22.
Hutchison IL, Ridout F, Cheung SMY, Shah N, Hardee P, Surwald C, et al. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. Br J Cancer. 2019;121(10):827–36.
D’Cruz AK, Vaish R, Kapre N, Dandekar M, Gupta S, Hawaldar R, et al. Elective versus therapeutic neck dissection in node-negative oral cancer. N Engl J Med. 2015;373(6):521–9.
Hasegawa Y, Tsukahara K, Yoshimoto S, Miura K, Yokoyama J, Hirano S, et al. Neck dissections based on sentinel lymph node navigation versus elective neck dissections in early oral cancers: a randomized, multicenter, and noninferiority trial. J Clin Oncol. 2021;39(18):2025–36.
Garrel R, Poissonnet G, Moya Plana A, Fakhry N, Dolivet G, Lallemant B, et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1–T2N0 Oral and oropharyngeal cancer. J Clin Oncol. 2020;38(34):4010–8.
Cramer JD, Sridharan S, Ferris RL, Duvvuri U, Samant S. Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Stage I to II Oral Cavity Cancer. Laryngoscope. 2019;129(1):162–9.
Candela FC, Kothari K, Shah JP. Patterns of cervical node metastases from squamous carcinoma of the oropharynx and hypopharynx. Head Neck. 1990;12(3):197–203.
Lim YC, Koo BS, Lee JS, Lim JY, Choi EC. Distributions of cervical lymph node metastases in oropharyngeal carcinoma: therapeutic implications for the N0 neck. Laryngoscope. 2006;116(7):1148–52.
Koyfman SA, Ismaila N, Crook D, D’Cruz A, Rodriguez CP, Sher DJ, et al. Management of the neck in squamous cell carcinoma of the oral cavity and oropharynx: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(20):1753–74.
Waldfahrer F, Hauptmann B, Iro H. Lymph node metastasis of glottic laryngeal carcinoma. Laryngorhinootologie. 2005;84(2):96–100.
Djordjevic V, Bukurov B, Arsovic N, Dimitrijevic M, Jesic S, Nesic V, et al. Prospective case-control study of efficacy of bilateral selective neck dissection in primary surgical treatment of supraglottic laryngeal cancers with clinically negative cervical findings (N0). Clin Otolaryngol. 2016;41(6):634–9.
Hicks WL Jr, Kollmorgen DR, Kuriakose MA, Orner J, Bakamjian VY, Winston J, et al. Patterns of nodal metastasis and surgical management of the neck in supraglottic laryngeal carcinoma. Otolaryngol Head Neck Surg. 1999;121(1):57–61.
Levendag P, Vikram B. The problem of neck relapse in early stage supraglottic cancer–results of different treatment modalities for the clinically negative neck. Int J Radiat Oncol Biol Phys. 1987;13(11):1621–4.
Lutz CK, Johnson JT, Wagner RL, Myers EN. Supraglottic carcinoma: patterns of recurrence. Ann Otol Rhinol Laryngol. 1990;99(1):12–7.
Agrawal A, Moon J, Davis RK, Sakr WA, Giri SP, Valentino J, et al. Transoral carbon dioxide laser supraglottic laryngectomy and irradiation in stage I, II, and III squamous cell carcinoma of the supraglottic larynx: report of Southwest Oncology Group Phase 2 Trial S9709. Arch Otolaryngol Head Neck Surg. 2007;133(10):1044–50.
Olsen KD, DeSanto LW, Pearson BW. Positive Delphian lymph node: clinical significance in laryngeal cancer. Laryngoscope. 1987;97(9):1033–7.
Plaat RE, de Bree R, Kuik DJ, van den Brekel MW, van Hattum AH, Snow GB, et al. Prognostic importance of paratracheal lymph node metastases. Laryngoscope. 2005;115(5):894–8.
Thaler ER, Montone K, Tucker J, Weinstein GS. Delphian lymph node in laryngeal carcinoma: a whole organ study. Laryngoscope. 1997;107(3):332–4.
Lucioni M, D’Ascanio L, De Nardi E, Lionello M, Bertolin A, Rizzotto G. Management of paratracheal lymph nodes in laryngeal cancer with subglottic involvement. Head Neck. 2018;40(1):24–33.
Amatsu M, Mohri M, Kinishi M. Significance of retropharyngeal node dissection at radical surgery for carcinoma of the hypopharynx and cervical esophagus. Laryngoscope. 2001;111(6):1099–103.
Chung EJ, Kim GW, Cho BK, Park HS, Rho YS. Pattern of lymph node metastasis in hypopharyngeal squamous cell carcinoma and indications for level VI lymph node dissection. Head Neck. 2016;38(Suppl 1):E1969–73.
Shah JP. Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. Am J Surg. 1990;160(4):405–9.
Yoshimoto S, Kawabata K. Retropharyngeal node dissection during total pharyngolaryngectomy for hypopharyngeal cancer. Auris Nasus Larynx. 2005;32(2):163–7.
Braakhuis BJ, Brakenhoff RH, Leemans CR. Treatment choice for locally advanced head and neck cancers on the basis of risk factors: biological risk factors. Ann Oncol. 2012;23(Suppl 10):x173–7.
Brana I, Siu LL. Locally advanced head and neck squamous cell cancer: treatment choice based on risk factors and optimizing drug prescription. Ann Oncol. 2012;23(Suppl 10):x178–85.
Oliver RJ, Clarkson JE, Conway DI, Glenny A, Macluskey M, Pavitt S, et al. Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. Cochrane Database Syst Rev. 2007;4:CD006205.
Iyer NG, Tan DS, Tan VK, Wang W, Hwang J, Tan NC, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer. 2015;121(10):1599–607.
Robertson AG, Soutar DS, Paul J, Webster M, Leonard AG, Moore KP, et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clin Oncol (R Coll Radiol). 1998;10(3):155–60.
Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, et al. Analysis of risk factors of predictive local tumor control in oral cavity cancer. Ann Surg Oncol. 2008;15(3):915–22.
Stenson KM, Kunnavakkam R, Cohen EE, Portugal LD, Blair E, Haraf DJ, et al. Chemoradiation for patients with advanced oral cavity cancer. Laryngoscope. 2010;120(1):93–9.
Haughey BH, Hinni ML, Salassa JR, Hayden RE, Grant DG, Rich JT, et al. Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck. 2011;33(12):1683–94.
Forastiere AA, Weber RS, Trotti A. Organ preservation for advanced larynx cancer: issues and outcomes. J Clin Oncol. 2015;33(29):3262–8.
Lango MN, Egleston B, Fang C, Burtness B, Galloway T, Liu J, et al. Baseline health perceptions, dysphagia, and survival in patients with head and neck cancer. Cancer. 2014;120(6):840–7.
Vainshtein JM, Wu VF, Spector ME, Bradford CR, Wolf GT, Worden FP. Chemoselection: a paradigm for optimization of organ preservation in locally advanced larynx cancer. Expert Rev Anticancer Ther. 2013;13(9):1053–64.
Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, Department of Veterans Affairs Laryngeal Cancer Study G, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324(24):1685–90.
Spaulding MB, Fischer SG, Wolf GT. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. J Clin Oncol. 1994;12(8):1592–9.
Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol. 2021;156:281–93.
Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349(22):2091–8.
Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Long-term results of RTOG 91–11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31(7):845–52.
Yu J, Tsay C, Sasaki C, Son YH, Decker RH, Mehra S, et al. Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs. Oral Oncol. 2021;122: 105585.
Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, et al. Cisplatin every 3 weeks versus weekly with definitive concurrent radiotherapy for squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 2019;111(5):490–7.
Mohamed A, Twardy B, Zordok MA, Ashraf K, Alkhoder A, Schrapp K, et al. Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis. Head Neck. 2019;41(5):1490–8.
Oliva M, Huang SH, Xu W, Su J, Hansen AR, Bratman SV, et al. Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. Eur J Cancer. 2019;118:112–20.
Perez CA, Wu X, Amsbaugh MJ, Gosain R, Claudino WM, Yusuf M, et al. High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck. Oral Oncol. 2017;67:24–8.
Spreafico A, Huang SH, Xu W, Granata R, Liu CS, Waldron JN, et al. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. Eur J Cancer. 2016;67:174–82.
Szturz P, Wouters K, Kiyota N, Tahara M, Prabhash K, Noronha V, et al. Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data. Oncologist. 2017;22(9):1056–66.
Sharma AKM, Bhasker S, Thakar A, Pramanik R, Biswas A, Kumar A, Sikka K, Singh AC, Mallick S, Kumar R, Deo SVS, Kakkar A, Baghmar S, Sehrawat A, Sethi P, Kumar A, Seth S, Upadhyay AD, Thulkar S. An open-label, noninferiority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial). In: J Clin Oncol 40 nsJ, 2022) 6004-6004., editor. ASCO; 2022; Chicago, IL; 2022.
Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999;17(1):409–22.
Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol. 1998;9(1):13–21.
Fountzilas G, Ciuleanu E, Dafni U, Plataniotis G, Kalogera-Fountzila A, Samantas E, et al. Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study. Med Oncol. 2004;21(2):95–107.
Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Final results of the 94–01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22(1):69–76.
Haddad R, Sonis S, Posner M, Wirth L, Costello R, Braschayko P, et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer. 2009;115(19):4514–23.
Tao Y, Auperin A, Sire C, Martin L, Khoury C, Maingon P, Bardet E, Kaminsky MC, Lapeyre M, Chatellier T, Alfonsi M, Pointreau Y, Jadaud E, Géry B, Zawadi A, Tourani JM, Laguerre B, Coutte A, Racadot S, Hasbini A, Malaurie E, Borel C, Meert N, Cornely A, Ollivier N, Casiraghi O, Sun XS, Bourhis J. Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial. J Clin Oncol. 2018 Jun 7:JCO2017762518. doi: 10.1200/JCO.2017.76.2518. Epub ahead of print. PMID: 29878867.
Patil VM NV, Menon NS, Laskar S, Budrukkar A, Swain M, Bhattacharjee A, Balaji A, Chaturvedi P, Chaukar DA, Pai PS, Nair SV, Purandare N, Agrawal A, Puranik A, Nawale KP, Mathrudev V, Prabhash K. Results of Phase III randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer unsuitable for cisplatin-based chemoradiation. In: J Clinical Oncol. 40 nsJ, 2022) LBA6003-LBA6003., editor. ASCO; 2022; Chicago, IL; 2022.
Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol. 1993;11(10):1873–8.
Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53(15):3579–84.
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.
Rosenthal DI, Harari PM, Giralt J, Bell D, Raben D, Liu J, et al. Association of human papillomavirus and p16 status with outcomes in the IMCL-9815 phase III registration trial for patients with locoregionally advanced oropharyngeal squamous cell carcinoma of the head and neck treated with radiotherapy with or without cetuximab. J Clin Oncol. 2016;34(12):1300–8.
Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393(10166):40–50.
Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled Phase III trial. Lancet. 2019;393(10166):51–60.
Rischin D, King M, Kenny L, Porceddu S, Wratten C, Macann A, et al. Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 1201)—a Trans-Tasman Radiation Oncology Group Study. Int J Radiat Oncol Biol Phys. 2021;111(4):876–86.
Gebre-Medhin M, Brun E, Engstrom P, Haugen Cange H, Hammarstedt-Nordenvall L, Reizenstein J, et al. ARTSCAN III: a randomized phase III study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer. J Clin Oncol. 2021;39(1):38–47.
Giralt J, Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G, et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015;16(2):221–32.
Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, et al. Effect of standard radiotherapy with cisplatin vs accelerated radiotherapy with panitumumab in locoregionally advanced squamous cell head and neck carcinoma: a randomized clinical trial. JAMA Oncol. 2017;3(2):220–6.
Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014;32(27):2940–50.
Patil VM, Noronha V, Joshi A, Agarwal J, Ghosh-Laskar S, Budrukkar A, et al. A randomized Phase III trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. Cancer. 2019;125(18):3184–97.
Mesia R, Henke M, Fortin A, Minn H, Yunes Ancona AC, Cmelak A, et al. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015;16(2):208–20.
Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol. 2013;31(11):1415–21.
Stuart J, Wong PAT-S, Saba NF, Shenouda G, Bumpous J, Wallace RE, Chung CH, El-Naggar AK, Gwede CK, Burtness B, Tennant P, Dunlap ME, Mell LK, Spencer S, Stokes WA, Yao M, Mitchell DL, Harris J, Curran WJ, Le Q-T. TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC). Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 6014-6014. In: 2021 ASCO Annual Meeting; 2021.
Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicenter, Phase III trial. Lancet Oncol. 2021;22(4):450–62.
Tao YXS, Sire C, Martin L, Alfonsi M, Prevost JB, Rives M, Lafond C, Tourani JM, Biau J, Geoffrois L, Coutte A, Liem X, Vauleon E, Drouet F, Pechery A, Guigay J, Wanneveich M, Aupérin A, Bourhis J. LBA38—pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. In: ESMO Virtual Congress 2020; 2020.
Bourhis J TY, Sun X, Sire C, Martin L, Liem X, Coutte A, Pointreau Y, Thariat J, Miroir J, Rolland F, Kaminsky M, Borel C, Maillard A, Sinigaglia L, Guigay J, Saada-Bouzid E, Even C, Aupérin A. LBA35-Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): randomized phase III GORTEC-REACH trial. In: AoOsS-S, editor. ESMO; 2021; 2021 https://doi.org/10.1016/annonc/annonc741.
Machiels J TY, Burtness B, Tahara M, Rischin D, Alves GV, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnal M, Licitra LF, Swaby R, Zhang Y, Gumuscu B, Bidadi B, Siu LL. LBA5 - Primary results of the phase III KEYNOTE-412 study: pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). In: AoOsS-S, editor. ESMO; 2022; Paris; 2022 https://doi.org/10.1016/annonc/annonc1089.
Clump DA ZD, Skinner HD, Ohr J, Fenton MJ, Normolle DP, Beitler JJ, Bauman JE, Ferris RL. A randomized phase II study evaluating concurrent or sequential fixed-dose immune therapy in combination with cisplatin and intensity-modulated radiotherapy in intermediate- or high-risk, previously untreated, locally advanced head and neck cancer (LA SCCHN). Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 6007-6007. In: J Clin Oncol 40 sa, editor. ASCO; 2022; Chicago, IL; 2022.
Sun XS, Tao Y, Le Tourneau C, Pointreau Y, Sire C, Kaminsky MC, et al. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study. Lancet Oncol. 2020;21(9):1173–87.
Bourhis J LTC, Calderon B, Martin L, Sire C, Pointreau Y, Ramee J, Coutte A, Boisselier P, Kaminsky-Forrett M, Delord J, Clatot F, Sun X, Villa J, Magne N, Elicin O, Damstrup L, Gollmer K, Crompton P, Tao Y. LBA33 - 5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in a randomized, phase II study. In: AoOsS-S, editor. ESMO; 2022; Paris; 2022 https://doi.org/10.1016/annonc/annonc1089.
Middleton MR, Dean E, Evans TRJ, Shapiro GI, Pollard J, Hendriks BS, et al. Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine +/- cisplatin in patients with advanced solid tumours. Br J Cancer. 2021;125(4):510–9.
Bhatia A CZ, Bruce J, Steuer CE, Zandberg DP, Riess JW, Mitchell D, Davis TH, Patel M, Kaur V, Arnold S, Owonikoko TK. 656MO - Phase I study of M6620 (VX-970, berzosertib) in combination with cisplatin and XRT in patients with locally advanced head and neck squamous cell carcinoma. In: AoOsS-S, editor. ESMO; 2022; Paris; 2022. https://doi.org/10.1016/annonc/annonc1056.
Hitt R, Lopez-Pousa A, Martinez-Trufero J, Escrig V, Carles J, Rizo A, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005;23(34):8636–45.
Janoray G, Pointreau Y, Garaud P, Chapet S, Alfonsi M, Sire C, et al. Long-term results of a multicenter randomized phase iii trial of induction chemotherapy with cisplatin, 5-fluorouracil, +/- docetaxel for larynx preservation. J Natl Cancer Inst. 2016;108(4).
Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised Phase III trial. Lancet Oncol. 2011;12(2):153–9.
Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357(17):1705–15.
Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695–704.
Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32(25):2735–43.
Geoffrois L, Martin L, De Raucourt D, Sun XS, Tao Y, Maingon P, et al. Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007–02 phase III randomized trial. J Clin Oncol. 2018;36(31):3077–83.
Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codeca C, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncol. 2017;28(9):2206–12.
Haddad R, O’Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised Phase III trial. Lancet Oncol. 2013;14(3):257–64.
Hitt R, Grau JJ, Lopez-Pousa A, Berrocal A, Garcia-Giron C, Irigoyen A, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014;25(1):216–25.
Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, et al. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, Phase II trial. Clin Cancer Res. 2020;26(19):5140–52.
Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen YH, Catalano PS, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial. JAMA Oncol. 2020;6(10):1563–70.
Vos JL, Elbers JBW, Krijgsman O, Traets JJH, Qiao X, van der Leun AM, et al. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nat Commun. 2021;12(1):7348.
Wise-Draper TM, Gulati S, Palackdharry S, Hinrichs BH, Worden FP, Old MO, et al. Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma. Clin Cancer Res. 2022;28(7):1345–52.
Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945–52.
Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937–44.
Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012;84(5):1198–205.
Bernier J, Cooper JS. Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence? Oncologist. 2005;10(3):215–24.
Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27(10):843–50.
Noronha V, Joshi A, Patil VM, Agarwal J, Ghosh-Laskar S, Budrukkar A, et al. Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial. J Clin Oncol. 2018;36(11):1064–72.
Kiyota NMT, Fujii H, Yamazaki T, Mitani H, Iwae S, Fujimoto Y, Onozawa Y, Hanai N, Ogawa T, Hara H, Monden N, Shimura E, Minami S, Fujii T, Tanaka K, Kodaira T, Mizusawa J, Nakamura K, Hayashi R. Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008). J Clin Oncol. 2020;38(15_suppl):6502 (2020 ASCO Annual Meeting; 2020).
Cooper JS, Fortpied C, Gregoire V, Le QT, Pajak TF, Zhang QE, et al. The role of postoperative chemoradiation for oropharynx carcinoma: a critical appraisal revisited. Cancer. 2017;123(1):12–6.
Trifiletti DM, Smith A, Mitra N, Grover S, Lukens JN, Cohen RB, et al. Beyond positive margins and extracapsular extension: evaluating the utilization and clinical impact of postoperative chemoradiotherapy in resected locally advanced head and neck cancer. J Clin Oncol. 2017;35(14):1550–60.
Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res. 2012;18(1):290–300.
Masica DL, Li S, Douville C, Manola J, Ferris RL, Burtness B, et al. Predicting survival in head and neck squamous cell carcinoma from TP53 mutation. Hum Genet. 2015;134(5):497–507.
Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357(25):2552–61.
Zenga J, Wilson M, Adkins DR, Gay HA, Haughey BH, Kallogjeri D, et al. Treatment outcomes for T4 oropharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2015;141(12):1118–27.
Saito Y, Hayashi R, Iida Y, Mizumachi T, Fujii T, Matsumoto F, et al. Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: multi-institutional observational study based on the national Head and Neck Cancer Registry of Japan. Cancer. 2020;126(18):4177–87.
Chera BS, Amdur RJ, Tepper JE, Tan X, Weiss J, Grilley-Olson JE, et al. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma. Cancer. 2018;124(11):2347–54.
Yom SS, Torres-Saavedra P, Caudell JJ, Waldron JN, Gillison ML, Xia P, et al. Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002). J Clin Oncol. 2021;39(9):956–65.
Wopken K, Bijl HP, van der Schaaf A, van der Laan HP, Chouvalova O, Steenbakkers RJ, et al. Development of a multivariable normal tissue complication probability (NTCP) model for tube feeding dependence after curative radiotherapy/chemo-radiotherapy in head and neck cancer. Radiother Oncol. 2014;113(1):95–101.
Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, et al. E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN Cancer Research Group. J Clin Oncol. 2017;35(5):490–7.
Chen AM, Felix C, Wang PC, Hsu S, Basehart V, Garst J, et al. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncol. 2017;18(6):803–11.
Rosenberg AJ, Agrawal N, Pearson A, Gooi Z, Blair E, Cursio J, et al. Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: optima paradigm expanded experience. Oral Oncol. 2021;122: 105566.
Miccio JA, Verma V, Kelly J, Kann BH, An Y, Park HS, et al. Impact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition. Oral Oncol. 2019;99:104447.
Quon H, O’Malley BW Jr, Weinstein GS. Transoral robotic surgery and a paradigm shift in the management of oropharyngeal squamous cell carcinoma. J Robot Surg. 2010;4(2):79–86.
Ferris RL, Flamand Y, Holsinger FC, Weinstein GS, Quon H, Mehra R, et al. A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311. Oral Oncol. 2020;110: 104797.
Moore EJ, Van Abel KM, Routman DM, Lohse CM, Price KAR, Neben-Wittich M, et al. Human papillomavirus oropharynx carcinoma: aggressive de-escalation of adjuvant therapy. Head Neck. 2021;43(1):229–37.
Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet. 2016;387(10022):1012–24.
Bei JX, Zuo XY, Liu WS, Guo YM, Zeng YX. Genetic susceptibility to the endemic form of NPC. Chin Clin Oncol. 2016;5(2):15.
Dai W, Zheng H, Cheung AK, Tang CS, Ko JM, Wong BW, et al. Whole-exome sequencing identifies MST1R as a genetic susceptibility gene in nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 2016;113(12):3317–22.
Li YY, Chung GT, Lui VW, To KF, Ma BB, Chow C, et al. Exome and genome sequencing of nasopharynx cancer identifies NF-kappaB pathway activating mutations. Nat Commun. 2017;18(8):14121.
Lin DC, Meng X, Hazawa M, Nagata Y, Varela AM, Xu L, et al. The genomic landscape of nasopharyngeal carcinoma. Nat Genet. 2014;46(8):866–71.
Zhang L, MacIsaac KD, Zhou T, Huang PY, Xin C, Dobson JR, et al. Genomic analysis of nasopharyngeal carcinoma reveals TME-based subtypes. Mol Cancer Res. 2017;15(12):1722–32.
Zheng H, Dai W, Cheung AK, Ko JM, Kan R, Wong BW, et al. Whole-exome sequencing identifies multiple loss-of-function mutations of NF-kappaB pathway regulators in nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 2016;113(40):11283–8.
Chang ET, Liu Z, Hildesheim A, Liu Q, Cai Y, Zhang Z, et al. Active and passive smoking and risk of nasopharyngeal carcinoma: a population-based case-control study in Southern China. Am J Epidemiol. 2017;185(12):1272–80.
Guo X, Johnson RC, Deng H, Liao J, Guan L, Nelson GW, et al. Evaluation of nonviral risk factors for nasopharyngeal carcinoma in a high-risk population of Southern China. Int J Cancer. 2009;124(12):2942–7.
Liu Z, Chang ET, Liu Q, Cai Y, Zhang Z, Chen G, et al. Quantification of familial risk of nasopharyngeal carcinoma in a high-incidence area. Cancer. 2017;123(14):2716–25.
Tsao SW, Yip YL, Tsang CM, Pang PS, Lau VM, Zhang G, et al. Etiological factors of nasopharyngeal carcinoma. Oral Oncol. 2014;50(5):330–8.
Au KH, Ngan RKC, Ng AWY, Poon DMC, Ng WT, Yuen KT, et al. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: a report of 3328 patients (HKNPCSG 1301 study). Oral Oncol. 2018;77:16–21.
Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009;27(22):3684–90.
Li XY, Chen QY, Sun XS, Liu SL, Yan JJ, Guo SS, et al. Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma. Eur J Cancer. 2019;110:24–31.
Tang LL, Guo R, Zhang N, Deng B, Chen L, Cheng ZB, et al. Effect of radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy on survival without disease relapse in patients with low-risk nasopharyngeal carcinoma: a randomized clinical trial. JAMA. 2022;328(8):728–36.
Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16(6):645–55.
Cao SM, Yang Q, Guo L, Mai HQ, Mo HY, Cao KJ, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial. Eur J Cancer. 2017;75:14–23.
Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a Phase III, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509–20.
Yang Q, Cao SM, Guo L, Hua YJ, Huang PY, Zhang XL, et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer. 2019;119:87–96.
Zhang B, Li MM, Chen WH, Zhao JF, Chen WQ, Dong YH, et al. Association of chemoradiotherapy regimens and survival among patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(10): e1913619.
Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019;381(12):1124–35.
Chen YP, Liu X, Zhou Q, Yang KY, Jin F, Zhu XD, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, Phase III trial. Lancet. 2021;398(10297):303–13.
Miao JLW, Tan SH, Li J-G, Yi J, Zhang Y, Gong X, Yanqun X, Chen Q-Y, Chen M, Lv X, Xia W, Tang L-Q, Deng X-W, Guo X, Mai H-Q, Han F, Chua MLK, Zhao C. Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized controlled phase III trial. J Clin Oncol. 2021;39(15_suppl):6005 (ASCO Annual Meeting; 2021).
Liu YP, Wen YH, Tang J, Wei Y, You R, Zhu XL, et al. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, Phase III trial. Lancet Oncol. 2021;22(3):381–90.
Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized Phase III trial. Nat Med. 2021;27(9):1536–43.
Yang Y, Qu S, Li J, Hu C, Xu M, Li W, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, Phase III trial. Lancet Oncol. 2021;22(8):1162–74.
Zhang L YY, Pan J, Chen X, Sun Y, Wang H RATIONALE-309: updated progression-free survival (PFS), PFS after next line of treatment, and overall survival from a Phase III double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer. Journal of Clinical Oncology 40, no. 36_suppl (December 20, 2022) 384950-384950.2022.
Chan ATC LV, Hong R, Ahn M, Chong WQ, Kim S, Fuang HG, Caguioa PB Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC). Annals of Oncology (2021) 32 (suppl_5): S786-S817. 10.1016/annonc/annonc704. ESMO. 2021.
Toh HCYM, Wang H, Hsieh C, Chitapanarux I, Ho KF, Hong R, Ang M, Colevas D, Sirachainan E, Lertbutsayanukul C, Ho GF, Samol J, Huang Z, Tan C, Ding C, Myo A. Randomized phase III VANCE study: gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC). Ann Oncol. 2022;33(suppl_7):S295–322. https://doi.org/10.1016/annonc/annonc1056. (ESMO; 2022).
Wright CM, Lee DY, Shimunov D, Carmona R, Barsky AR, Sun L, et al. Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery. Oral Oncol. 2021;121: 105509.
Argiris A, Li S, Ghebremichael M, Egloff AM, Wang L, Forastiere AA, et al. Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. Ann Oncol. 2014;25(7):1410–6.
Fakhry C, Zhang Q, Nguyen-Tan PF, Rosenthal D, El-Naggar A, Garden AS, et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol. 2014;32(30):3365–73.
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.
Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro Jr. G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, Phase III study. Lancet. 2019;394(10212):1915–28.
Dzienis MRCJ, Fuentes CS, Hansen AR, Nordlinger MJ, Pastor AV, Oppelt P, Neki A, Gregg RW, Lima IPF, Franke FA, da Cunha Jr GF, Tseng JE, Loree T, Joshi AJ, mccarthy JS, Naicker N, Sidi Y, Gumuscu B, De Castro Jr G,. Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): phase IV KEYNOTE-B10 study. Ann Oncol. 2022;33(suppl_7):S295–322. https://doi.org/10.1016/annonc/annonc1056. (ESMO; 2022).
Emancipator K, Huang L, Aurora-Garg D, Bal T, Cohen EEW, Harrington K, et al. Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Mod Pathol. 2021;34(3):532–41.
Cohen EEW, Soulieres D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, Phase III study. Lancet. 2019;393(10167):156–67.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67.
Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002;29(1 Suppl 4):27–36.
Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised Phase III trial. Lancet Oncol. 2015;16(5):583–94.
Seiwert TY, Fayette J, Cupissol D, Del Campo JM, Clement PM, Hitt R, et al. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 2014;25(9):1813–20.
Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171–7.
Mountzios G, Rampias T, Psyrri A. The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact. Ann Oncol. 2014;25(10):1889–900.
Untch BR, Dos Anjos V, Garcia-Rendueles MER, Knauf JA, Krishnamoorthy GP, Saqcena M, et al. Tipifarnib inhibits HRAS-driven dedifferentiated thyroid cancers. Cancer Res. 2018;78(16):4642–57.
Gilardi M, Wang Z, Proietto M, Chilla A, Calleja-Valera JL, Goto Y, et al. Tipifarnib as a precision therapy for HRAS-mutant head and neck squamous cell carcinomas. Mol Cancer Ther. 2020;19(9):1784–96.
Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, et al. Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations. J Clin Oncol. 2021;39(17):1856–64.
Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol. 2020;31(7):942–50.
Argiris AKH, Tahara M, Ferris RL, Gillison M, Fayette J, Daste A, Koralewski P, Mesia Nin R, Saba NF, Mak M, Álvarez Avitia MA, Guminski A, Müller-Richter U, Kiyota N, Roberts M, Khan TA, Miller-Moslin K, Wei L, Robert Haddad R. Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): final results of CheckMate 651. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741. In: ESMO Congress; 2021: European Society for Medical Oncology (ESMO) Congress 2021; September 16-21, 2021. Abstract LBA36; 2021.
Yentz S, Smith D. Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy. BioDrugs. 2018;32(4):311–7.
Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, et al. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037). J Clin Oncol. 2018;36(32):3223–30.
Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a Phase III, randomised, double-blind study. Lancet Oncol. 2019;20(8):1083–97.
Kontos F, Michelakos T, Kurokawa T, Sadagopan A, Schwab JH, Ferrone CR, et al. B7–H3: an attractive target for antibody-based immunotherapy. Clin Cancer Res. 2021;27(5):1227–35.
Zhang SS, Tang J, Yu SY, Ma LI, Wang F, Xie SL, et al. Expression levels of B7–H3 and TLT-2 in human oral squamous cell carcinoma. Oncol Lett. 2015;10(2):1063–8.
Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021;22(6):883–92.
Chung CH, Bonomi M, Steuer CE, Li J, Bhateja P, Johnson M, et al. Concurrent cetuximab and nivolumab as a second-line or beyond treatment of patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results of phase I/II study. Cancers (Basel). 2021;13(5).
Yang J, Yan J, Liu B. Targeting VEGF/VEGFR to Modulate Antitumor Immunity. Front Immunol. 2018;9:978.
Taylor MH, Lee CH, Makker V, Rasco D, Dutcus CE, Wu J, et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol. 2020;38(11):1154–63.
Saba NF EA, McCook-Veal A, Patel M, Schmitt NC, Stokes WA, Bates JE, Rudra S, Abousaud MI, Muzaffar J, Kirtane K, Teng Y, Steuer CE, Shin DM, Liu Y, Chung CH. A phase II trial of pembrolizumab and cabozantinib in patients (pts) with recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC). 2022: J Clin Oncol 40. 2022 (suppl 16; abstr 6008).
Amatore F, Gorvel L, Olive D. Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy. Expert Opin Biol Ther. 2020;20(2):141–50.
Solinas C, Gu-Trantien C, Willard-Gallo K. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. ESMO Open. 2020;5(1).
Sousa LG, Rajapakshe K, Rodriguez Canales J, Chin RL, Feng L, Wang Q, Barrese TZ, Massarelli E, William W, Johnson FM, Ferrarotto R, Wistuba I, Coarfa C, Lee J, Wang J, Melief CJM, Curran MA, Glisson BS. ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response. J Immunother Cancer. 2022 Feb;10(2):e004232. https://doi.org/10.1136/jitc-2021-004232. PMID: 35193933; PMCID: PMC9066369.
Morris VK, Jazaeri AA, Westin SN, Pettaway CA, George S, Huey R, Onstad M, Tu S-M, Wang J, Shafer A, Johnson B, Xiao L, Vining DJ, Guo M, Yuan Y, Frumovitz MM. Phase II trial of MEDI0457 and durvalumab for patients with recurrent/metastatic HPV-associated cancers. J Clin Oncol. 2021;39(15 suppl):2595–2595 (ASCO Annual Meeting; 2021).
Chung CHCA, Adkins DR, Park JC, Rodriguez CP, Gibson MK, Sukari A, Burtness BA, Johnson F, Julian RA, Saba NF, Dunn LA, Seiwert TY, Worden FP, Muzaffar J, Haddad RY, Gabrail NY, Bauman JE, Chaney M, Agensky L, Goel A, Lynam R, Margossian SP, Moniz RJ, Quayle SN, Pienta K, Levisetti M, Pai SI. A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer. J Immunother Cancer. 2022;10(Suppl 2):A1–1595 (SITC Annual Meeting; 2022).
Pellom ST, Smalley Rumfield C, Morillon YM, 2nd, Roller N, Poppe LK, Brough DE, et al. Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009. JCI Insight. 2021;6(7).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No external funding was used in the preparation of this manuscript.
Competing Interests
Aarti Bhatia: Research funding from Boehringer-Ingelheim and Genentech. Consultant fees from Regeneron, Sanofi-Genzyme, and Merck. Barbara Burtness: Consulting for Cue Biopharma, Debio, Genentech, IO Biotech, Kura, ALX Oncology, Merck, Merck KgA, Vaccinex, Exelexis, Glaxo Smith Kline. Research funding from Bristol Myers Squibb, Cue BioPharma, Exelexis, Merck, Merck KgA, RBN.
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Both authors AB and BB consent to the publication of this manuscript.
Availability of data and material
Not applicable.
Code availability
Not applicable.
Authors' contributions
Both authors AB and BB contributed equally to the preparation of this manuscript.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Bhatia, A., Burtness, B. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update. Drugs 83, 217–248 (2023). https://doi.org/10.1007/s40265-023-01835-2
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-023-01835-2